Lantern Pharma Inc. (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The event will include participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia, who will present the platform's capabilities, commercial architecture, competitive positioning and revenue strategy.
The briefing represents a significant demonstration of how artificial intelligence is transforming oncology drug development. Lantern Pharma's approach leverages its proprietary RADR® platform, which uses over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms to accelerate drug discovery. According to company information, this AI-driven approach has enabled Lantern to advance newly developed drug programs from initial AI insights to first-in-human clinical trials in just 2–3 years at approximately $1.0–2.5 million per program.
The company's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD, addressing the significant unmet needs in rare cancer treatment. Lantern has established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of promising therapies for CNS and brain cancers, further demonstrating the strategic application of their AI capabilities.
For investors and industry observers, the April briefing provides critical insight into how AI technologies are reshaping pharmaceutical development economics. The ability to dramatically reduce both timelines and costs while addressing rare cancers represents a potential paradigm shift in how treatments reach patients. Additional information about the company is available through their newsroom at https://ibn.fm/LTRN.
The demonstration of withZeta.ai comes at a time when artificial intelligence applications in healthcare are gaining increasing attention from both the scientific community and financial markets. As described in the announcement, withZeta.ai represents what Lantern calls "the first multi-agentic AI co-scientist" specifically designed for rare cancer applications, suggesting a sophisticated approach to collaborative AI systems working alongside human researchers.
This development matters because rare cancers collectively affect millions of patients worldwide but often receive limited research investment due to smaller patient populations and higher development risks. AI platforms like those developed by Lantern Pharma could potentially overcome these economic barriers by making drug discovery more efficient and cost-effective. The company's progress in advancing multiple drug candidates, including a Phase 2 clinical program and planned Phase 1b/2a clinical trials, demonstrates the practical application of their technology beyond theoretical models.
